Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report details a specific share repurchase transaction executed on October 5, 2012, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metrics disclosed relate to the share buyback and capital structure:
- Shares Purchased: 250,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,469.5 pence per share; lowest price paid was 1,452 pence per share.
- Treasury Holdings (Settled): 503,515,427 shares (9.25% of total issued share capital).
- Treasury Holdings (Including Unsettled): 504,465,427 shares (10.21% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,941,154,782 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the purchase of 250,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.21% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. It is a compliance disclosure regarding share repurchases under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (503,515,427 settled) against the company's latest capitalization table.
- Confirm the total voting rights denominator (4,941,154,782 shares) for disclosure threshold calculations.
- Check the settlement status of the 950,000 shares purchased but not yet settled to confirm the 10.21% voting rights figure.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.